| Literature DB >> 26983820 |
Abstract
The German Act on the Reform of the Market for Medicinal Products (AMNOG) will lead to rapid disappearance of many new psychotropic drugs from the market in Germany over the next few years or their not being introduced in the first place. This article lists the reasons and discusses possible solutions. In the long term, the AMNOG could not only lead to an improvement of psychopharmacology but also contribute to the development of psychiatry as a whole, especially if its standards become an international reference.Entities:
Keywords: Benefit risk assessment; Clinical trial; Drug evaluation; Health technology assessment; Psychopharmacology
Mesh:
Substances:
Year: 2016 PMID: 26983820 DOI: 10.1007/s00115-016-0095-z
Source DB: PubMed Journal: Nervenarzt ISSN: 0028-2804 Impact factor: 1.214